CINmetrics: an R package for analyzing copy number aberrations as a measure of chromosomal instability

Vishal H. Oza[1], Jennifer L. Fisher[1], Roshan Darji[2] and Brittany N. Lasseigne[1]

[1] Department of Cell, Developmental and Integrative Biology, University of Alabama - Birmingham, Birmingham, AL, United States of America
[2] HudsonAlpha Institute for Biotechnology, Huntsville, AL, United States of America

ABSTRACT

Genomic instability is an important hallmark of cancer and more recently has been identified in others like neurodegenrative diseases. Chromosomal instability, as a measure of genomic instability, has been used to characterize clinical and biological phenotypes associated with these diseases by measuring structural and numerical chromosomal alterations. There have been multiple chromosomal instability scores developed across many studies in the literature; however, these scores have not been compared because of the lack of a single tool available to calculate and facilitate these various metrics. Here, we provide an R package CINmetrics, that calculates six different chromosomal instability scores and allows direct comparison between them. We also demonstrate how these scores differ by applying CINmetrics to breast cancer data from The Cancer Genome Atlas (TCGA). The package is available on CRAN at https://cran.rproject.org/package=CINmetrics and on GitHub at https://github.com/lasseignelab/CINmetrics.

Subjects Computational Biology, Genomics, Oncology
Keywords Chromosomal instability, R package, Genomic instability, Cancer, CINmetrics, Copy number aberration

INTRODUCTION

Genomic instability, one of the hallmarks of cancer and aging, is measured in many forms such as chromosomal instability, microsatellite instability, and instability characterized by increased frequency of base-pair mutations (*Bakhoum & Cantley, 2018*; *Pikor et al., 2013*; *Negrini, Gorgoulis & Halazonetis, 2010*; *López-Otín et al., 2013*). Particularly, chromosomal instability (CIN) is associated with cancer progression, tumor immunity, and inflammation (*Pikor et al., 2013*; *Bach, Zhang & Sood, 2019*). Recently, CIN has been shown to contribute to diseases other than cancer, including neurodegenerative diseases (*Hou et al., 2017*; *Yurov, Vorsanova & Iourov, 2019*).

CIN is broadly defined as the change in number and structure of chromosomes (*Vargas-Rondón, Villegas & Rondón-Lagos, 2017*). Since CIN involves simultaneous and ongoing copy number changes, it is a dynamic phenotype that leads to intratumoral heterogeneity. In many published studies, CIN has been measured in proxy by capturing errors during anaphase segregation in tumor specimens or indirectly by measuring

numerical and structural chromosomal alterations across cell populations (segmental aneuploidy) (*Baumbusch et al., 2013*; *Davison et al., 2014*; *Roylance et al., 2011*; *Bonnet et al., 2012*). However, they do not measure the state or rate of chromosomal change, which is a limitation of array based and comparative genomic hybridization (CGH) methods (*Geigl et al., 2008*; *Lepage et al., 2019*). There have been various CIN scores developed across multiple studies involving different cancers which calculate numerical and structural alterations in the chromosome (*McGranahan et al., 2012*). The differences in calculation of these scores have been associated with different clinical and biological phenotypes (*Baumbusch et al., 2013*; *Davison et al., 2014*; *Roylance et al., 2011*; *Bonnet et al., 2012*); however, there has been no systematic comparison of different CIN scores and how they vary across and within different cancers. The primary reason being lack of availability of computational framework to calculate these CIN scores. While other packages are available to calculate chromosomal instability (*Song et al., 2017*), they are limited to a single chromosomal instability score and do not provide a framework to calculate and compare other CIN scores. Here, we provide an R package that provides a unified framework to calculate multiple CIN metrics to quantify segmental aneuploidy accumulations in a sample on same dataset. This package will accelerate chromosomal instability studies by facilitating score comparisons across cancers or other diseases.

METHODS

The chromosomal instability metrics were mined from the cancer literature and implemented as functions in our CINmetrics R package, based on their ability to detect either structural, numerical, or whole genome instability. The six functions (*tai, taiModified, cna, countingBreakPoints, countingBaseSegments, fga*) are outlined below based on the similarity of the algorithms used to calculate them.

Total aberration index *(tai)* and modified total aberration index *(taiModified)*

Total Aberration Index (TAI) was proposed by *Baumbusch et al. (2013)* to measure the genomic aberrations in serous ovarian cancers. TAI calculates absolute area under the curve for a copy number segment profile generated by piecewise constant fitting (PCF) algorithm (*Baumbusch et al., 2008*). Biologically, TAI can be interpreted as absolute deviation from the normal copy number state averaged over all genomic locations. TAI provides a numerical measure in terms of both prevalence as well as the genomic size of copy number variations in tumors. One of the limitations of TAI is that since it was designed for studying advanced stage ovarian tumors, short aberrations found in early stage tumors have low impact on TAI. Therefore, TAI should be used to study the global scale genomic disorganization most likely to occur in late stage tumors.

   tai implemented in CINmetrics takes into account only those sample values that are in aberrant copy number state, *i.e.,* has a mean segment value of less than or equal to -0.2 and greater than or equal to $+0.2$, without taking into account whether it is a deletion or

amplification.

$$Total\ Aberration\ Index = \frac{\sum_{i=1}^{R} d_i \cdot |y_{S_i}|}{\sum_{i=1}^{R} d_i} \tag{1}$$

where $y_{S_i} \leq -0.2$ and $y_{S_i} \geq +0.2$ represents the mean segment value, d_i represents the segment length, and R represents the total number of segments. Alternatively, *taiModfied* takes into account all the mean segment values and thus preserves the "directionality" of the score. In other words, *taiModified* retains the "directionality" of amplification or deletion. Negative modified tai value means there are more large deletions in the sample since the negative segment mean values are driving the metric.

$$Modified\ Total\ Aberration\ Index = \frac{\sum_{i=1}^{R} d_i \cdot y_{S_i}}{\sum_{i=1}^{R} d_i} \tag{2}$$

where y_{S_i} represents the mean segment value, d_i represents the segment length, and R represents the total number of segments.

Copy number abnormality *(CNA)* and number of break points *(countingBreakPoints)*

Copy number abnormality (CNA) was developed by *Davison et al. (2014)* for studying aneuploidy in superficial gastroesophageal adenocarcinoma. An individual CNA is defined as the segment with copy number outside the predefined range of 1.7 to 2.3 where two indicates no loss or gain (assuming that the tumor is diploid) as determined by the Partek segmentation algorithm (*Grayson & Aune, 2011*). Total CNA for the sample can thus be defined as total number of individual CNAs. CNA represents a measure of segmental aneuploidy. *cna* implemented in CINmetrics is similar except we define individual CNA as the segment with copy number less than or equal to −0.2 and greater than or equal to +0.2 with segment mean of 0 indicating no loss or gain. We chose ±0.2 as a conservative cutoff for TCGA data as described in *Laddha et al. (2014)*. The users can modify the cutoff by modifying *segmentMean* parameter.

$$Total\ Copy\ Number\ Abnormality = \sum_{i=1}^{R} n_i \tag{3}$$

where n_i represents number of segments with $y_{S_i} \leq -0.2$ and $y_{S_i} \geq +0.2$, R represents the total number of segments with the minimum segment length d_i greater than or equal to 10.

countingBreakPoints is similar to the total breakpoints implemented in *Lee et al. (2011)*. Segments with mean less than or equal to −0.2 and greater than or equal to +0.2 and that contain a number of probes above the user defined threshold, are counted and then the value is doubled to account for 3′ and 5′ ends. This metric yields similar relative distribution results to *cna*, however there is no minimum segment length (d_i) filter so the actual metric values differ (they will be higher for *countingBreakPoints*).

$$Number\ of\ Break\ Points = \sum_{i=1}^{R} (n_i \cdot 2) \tag{4}$$

Oza et al. (2023), *PeerJ*, DOI 10.7717/peerj.15244

3/11

where n_i represents number of segments with $y_{S_i} \leq -0.2$ and $y_{S_i} \geq +0.2$ and R represents the total number of segments.

Counting altered base segments *(countingBaseSegments)* and the fraction of the genome altered *(fga)*

Counting altered base segments and fraction of the genome altered are modified implementations of the Genome Instability Index (GII) as described in *Chin et al. (2007)*. The GII was computed in two different ways, both based on calculating common regions of alteration (CRA). These approaches show high concordance.

$$Number\ of\ Altered\ Bases = \sum_{i=1}^{R} d_i \tag{5}$$

where d_i represents length of segments with $y_{S_i} \leq -0.2$ and $y_{S_i} \geq +0.2$ and R represents the total number of segments.

fga implemented in our package is based on identifying CRAs as fraction of the genome altered. Therefore, the *fga* values are normalized by dividing it by the length of the genome covered. *countingBaseSegments* on the other hand calculates the CRAs.

$$Fraction\ Genome\ Altered = \frac{\sum_{i=1}^{R} d_i}{G} \tag{6}$$

where d_i represents length of segments with $y_{S_i} \leq -0.2$ and $y_{S_i} \geq +0.2$, G represents genome length covered, and R represents the total number of segments. The default value is calculated by adding length of each probe on Affymetrix 6.0 array file (snp6.na35.remap.hg38.subset.txt.gz) found here (*GDC, 2023*) after excluding the sex chromosomes. One important difference to note is that in the original GII calculations, the algorithm merges the overlapping regions between samples, whereas *fga* and *countingBaseSegements* implemented in CINmetrics package do not merge overlapping regions, since TCGA segments are not overlapping. However, if the user is using their own segmentation algorithm, they should make sure that the segments are not overlapping otherwise it will lead to erroneous results.

RESULTS

We used harmonized masked copy number segment data for breast cancer (BRCA) from The Cancer Genome Atlas (*Cancer Genome Atlas Network, 2012*; *Cerami et al., 2012*) to visualize and compare the chromosomal instability metrics implemented in the CINmetrics package. We chose the breast cancer data as it has been shown to exhibit chromosomal instability and thus provides a robust dataset for applying CINmetrics *e.g.,* (*Duijf et al., 2019*; *Voutsadakis, 2021*). Figure 1A shows the distribution of CINmetrics in BRCA data for normal and tumor samples. The metrics have been $\log_{10}$ scaled to allow for comparison between them. *cna*, *countingBreakPoints*, *fga*, and *countingBaseSegments* show an overall pattern of increased genomic instability in tumor samples compared to normal. However, the difference in mean and standard deviation between the two classes(normal and tumor) is very different between these metrics. *tai* and *taiModified* scores show greater overlap

Figure 1 CINmetrics applied to the BRCA dataset from TCGA, (A) the distribution of metrics between normal (red) and tumor (grey) samples, where the black dot indicates the mean and the black line indicates the standard deviation and (B) heatmap of the spearman correlation and complete linkage clustering of the metrics in normal and tumor samples.

Full-size 🖾 DOI: 10.7717/peerj.15244/fig-1

between normal and tumor samples compared to other metrics. As mentioned earlier, *tai* and *taiModified* are best suited for late stage cancers (*Baumbusch et al., 2013*), thus should be used as a measure for studying overall genomic disorganization in individual patients with advanced tumors and not as a measure of genomic instability comparison between normal and tumor samples, as we further demonstrate here.

To further understand and characterize the relationship between various metrics implemented in CINmetrics, we performed spearman correlation (*Spearman, 1904*), followed by complete linkage clustering (*Vijaya, Sharma & Batra, 2019*) as shown in Fig. 1B. This clustering further demonstrated that *cna*, *countingBreakPoints*, *fga*, and *countingBaseSegments* are more similar and therefore highly correlated compared to *tai* and *taiModified*. Furthermore, this relationship is preserved in both normal and tumor samples indicating the four metrics show consistent results and can be used for comparing genomic instability between the two conditions.

We also looked at how the metrics are affected by potential confounders such as tumor purity (defined as the fraction of cancerous cells in tumor samples) and ploidy levels in tumor samples in the BRCA dataset. We obtained the purity and ploidy data for BRCA calculated using ABSOLUTE algorithm (*Carter et al., 2012*) from the NIH Genomic Data Commons Portal (*The Pan-Cancer Atlas, 2022*). ABSOLUTE jointly infers tumor purity and ploidy levels from allele-specific copy number levels from a large sample collection and precomputed models of recurrent cancer karyotypes (*Carter et al., 2012*).

For purity, the purity score had a range between 0 and 1 for each sample, with 1 being the highest purity (Fig. 2A). We divided the score in four quantiles and plotted the density of the samples in each quantile against the CINmetrics scores (Fig. 2). All CINmetrics had relatively lower scores for samples with less purity (1st Quantile). Interestingly, *tai* showed a distinct increase in the score with the increase in purity of samples. These can be due

Figure 2 Distribution of sample purity scores and CINmetrics applied to BRCA dataset from TCGA compared to sample purity, (A) sample purity score quantile distribution (B) *tai*, (C) *taiModified*, (D) *cna*, (E) *countingBreakPoints*, (F) *fga*, and (G) *countingBaseSegments*.

Full-size 🖾 DOI: 10.7717/peerj.15244/fig-2

to more purer samples having higher segmental aneuploidy and therefore more segments having mean segment value of greater than 0.2. *taiModified* showed the same distribution across the four quantiles.

For ploidy, we looked at the density of samples with different ploidy numbers against the CINmetrics scores (Fig. 3). Samples that were diploid (2n) had the lowest score across *cna*, *countingBreakPoints*, *fga*, and *countingBaseSegments*; however not in *tai* and *taiModified*. *cna* and *countingBreakPoints* were developed to study aneuploidy (*Davison et al., 2014*; *Lee et al., 2011*), and they show higher scores corresponding to higher ploidy levels.

Figure 3 Distribution of CINmetrics applied to the BRCA dataset from TCGA compared to sample ploidy levels, (A) *tai*, (B) *taiModified*, (C) *cna*, (D) *countingBreakPoints*, (E) *fga*, and (F) *countingBaseSegments*.

Full-size ⊡ DOI: 10.7717/peerj.15244/fig-3

CONCLUSIONS

CIN has been one of the most important factors in understanding disease etiology and progression in cancer (*Pikor et al., 2013*; *Bach, Zhang & Sood, 2019*) and is becoming increasingly recognized for others like neurodegenerative diseases (*Hou et al., 2017*; *Yurov, Vorsanova & Iourov, 2019*). Also, genomic instability has been associated with biological variables such as sex, age, and tissue (*Fischer & Riddle, 2018*). Numerous methods have been developed to quantitate and characterize the role of chromosomal instability in specific cancers, however, lack of comprehensive tools that calculates these metrics has limited direct comparison between them. Here, we have collected chromosomal instability metrics from the literature and provide them as an R package and associated vignette that allows for reproducible calculations and comparisons. Further, we used BRCA data from

The Cancer Genome Atlas to show how the metrics relate to each other. One limitation of these scores is that if the aneuploidy arose at the outset of cancer, these scores might give high scores even in absence of CIN. The advent of next generation sequencing and single cell technologies allows for better measurement of the state of chromosomal change as well as cell-to-cell variability which is often masked in traditional chromosomal instability scores (*Geigl et al., 2008*; *Lepage et al., 2019*). Another limitation of the package is that it relies on array based intensity scores for the calculations of copy number variation and therefore cannot be used with next generation sequencing data. This package nevertheless, provides a useful framework to better characterize and understand genomic instability in cancer.

ACKNOWLEDGEMENTS

ADDITIONAL INFORMATION AND DECLARATIONS

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Vishal H. Oza conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
- Jennifer L. Fisher conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Roshan Darji conceived and designed the experiments, performed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Brittany N. Lasseigne conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

Data Availability

The following information was supplied regarding data availability:

The code is available on CRAN: https://cran.r-project.org/package=CINmetrics.

The data and code are available at GitHub and Zenodo: https://github.com/lasseignelab/CINmetrics.

Vishal H. Oza. (2023). lasseignelab/CINmetrics: inital release of CINmetrics R package repo (v1.1.0). Zenodo. https://doi.org/10.5281/zenodo.7750898.

REFERENCES

Bach D-H, Zhang W, Sood AK. 2019. Chromosomal instability in tumor initiation and development. *Cancer Research* **79**(**16**):3995–4002.

Bakhoum SF, Cantley LC. 2018. The multifaceted role of chromosomal instability in cancer and its microenvironment. *Cell* **174**(**6**):1347–1360 DOI 10.1016/j.cell.2018.08.027.

Baumbusch LO, Aarøe J, Johansen FE, Hicks J, Sun H, Bruhn L, Gunderson K, Naume B, Kristensen VN, Liestøl K, Børresen-Dale A-L, Lingjaerde OC. 2008. Comparison of the agilent, ROMA/NimbleGen and illumina platforms for classification of copy number alterations in human breast tumors. *BMC Genomics* **9**:379 DOI 10.1186/1471-2164-9-379.

Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemad-moghadam D, Alsop K, Brown P, Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DDL, Kristensen GB, Lingjærde OC, Børresen-Dale A-L. 2013. High levels of genomic aberrations in serous ovarian cancers are associated with better survival. *PLOS ONE* **8**(**1**):e54356 DOI 10.1371/journal.pone.0054356.

Bonnet F, Guedj M, Jones N, Sfar S, Brouste V, Elarouci N, Banneau G, Orsetti B, Primois C, De Lara CT, Debled M, De Mascarel I, Theillet C, Sévenet N, De Reynies A, MacGrogan G, Longy M. 2012. An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis. *BMC Medical Genomics* **5**:54 DOI 10.1186/1755-8794-5-54.

Cancer Genome Atlas Network. 2012. Comprehensive molecular portraits of human breast tumours. *Nature* **490**(**7418**):61–70 DOI 10.1038/nature11412.

Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, Laird PW, Onofrio RC, Winckler W, Weir BA, Beroukhim R, Pellman D, Levine DA, Lander ES, Meyerson M, Getz G. 2012. Absolute quantification of somatic DNA alterations in human cancer. *Nature Biotechnology* **30**(**5**):413–421 DOI 10.1038/nbt.2203.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discovery* **2**(**5**):401–404 DOI 10.1158/2159-8290.CD-12-0095.

Oza et al. (2023), *PeerJ*, DOI 10.7717/peerj.15244

9/11

Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Thorne NP, Costa JL, Pinder SE, Van de Wiel MA, Green AR, Ellis IO, Porter PL, Tavaré S, Brenton JD, Ylstra B, Caldas C. 2007. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. *Genome Biology* **8(10)**:R215 DOI 10.1186/gb-2007-8-10-r215.

Davison JM, Yee M, Krill-Burger JM, Lyons-Weiler MA, Kelly LA, Sciulli CM, Nason KS, Luketich JD, Michalopoulos GK, LaFramboise WA. 2014. The degree of segmental aneuploidy measured by total copy number abnormalities predicts survival and recurrence in superficial gastroesophageal adenocarcinoma. *PLOS ONE* **9(1)**:e79079 DOI 10.1371/journal.pone.0079079.

Duijf PHG, Nanayakkara D, Nones K, Srihari S, Kalimutho M, Khanna KK. 2019. Mechanisms of genomic instability in breast cancer. *Trends in Molecular Medicine* **25(7)**:595–611 DOI 10.1016/j.molmed.2019.04.004.

Fischer KE, Riddle NC. 2018. Sex differences in aging: genomic instability. *The Journals of Gerontology Series A Biological Sciences and Medical Sciences* **73(2)**:166–174 DOI 10.1093/gerona/glx105.

Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR. 2008. Defining 'chromosomal instability'. *Trends in Genetics* **24(2)**:64–69 DOI 10.1016/j.tig.2007.11.006.

Genomic Data Commons (GDC). 2023. GDC reference files. *GDC reference files. Available at* https://gdc.cancer.gov/about-data/gdc-data-processing/gdc-reference-files (accessed on NA-NA-2023).

Grayson BL, Aune TM. 2011. A comparison of genomic copy number calls by Partek Genomics Suite, Genotyping Console and Birdsuite algorithms to quantitative PCR. *BioData Mining* **4**:8 DOI 10.1186/1756-0381-4-8.

Hou Y, Song H, Croteau DL, Akbari M, Bohr VA. 2017. Genome instability in Alzheimer disease. *Mechanisms of Ageing and Development* **161(Pt A)**:83–94 DOI 10.1016/j.mad.2016.04.005.

Laddha SV, Ganesan S, Chan CS, White E. 2014. Mutational landscape of the essential autophagy gene BECN1 in human cancers. *Molecular Cancer Research* **12(4)**:485–490 DOI 10.1158/1541-7786.MCR-13-0614.

Lee AJX, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IPM, Howell M, Kschischo M, Swanton C. 2011. Chromosomal instability confers intrinsic multidrug resistance. *Cancer Research* **71(5)**:1858–1870.

Lepage CC, Morden CR, Palmer MCL, Nachtigal MW, McManus KJ. 2019. Detecting chromosome instability in cancer: approaches to resolve cell-to-cell heterogeneity. *Cancers* **11(2)**:226 DOI 10.3390/cancers11020226.

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. 2013. The hallmarks of aging. *Cell* **153(6)**:1194–1217 DOI 10.1016/j.cell.2013.05.039.

McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C. 2012. Cancer chromosomal instability: therapeutic and diagnostic challenges. *EMBO Reports* **13(6)**:528–538 DOI 10.1038/embor.2012.61.

Negrini S, Gorgoulis VG, Halazonetis TD. 2010. Genomic instability—an evolving hallmark of cancer. *Nature Reviews Molecular Cell Biology* **11(3)**:220–228 DOI 10.1038/nrm2858.

Pikor L, Thu K, Vucic E, Lam W. 2013. The detection and implication of genome instability in cancer. *Cancer and Metastasis Reviews* **32(3–4)**:341–352 DOI 10.1007/s10555-013-9429-5.

Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Kschischo M, Szallasi Z, Swanton C. 2011. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. *Cancer Epidemiology, Biomarkers & Prevention* **20(10)**:2183–2194 DOI 10.1158/1055-9965.EPI-11-0343.

Song L, Bhuvaneshwar K, Wang Y, Feng Y, Shih I-M, Madhavan S, Gusev Y. 2017. CINdex: a bioconductor package for analysis of chromosome instability in DNA copy number data. *Cancer Informatics* **16**:1176935117746637.

Spearman C. 1904. The proof and measurement of association between two things. *The American Journal of Psychology* **15(1)**:72–101.

The Pan-Cancer Atlas. 2022. The Pan-Cancer Atlas. *Available at https://gdc.cancer.gov/about-data/publications/pancanatlas* (accessed on NA-NA-2022).

Vargas-Rondón N, Villegas VE, Rondón-Lagos M. 2017. The role of chromosomal instability in cancer and therapeutic responses. *Cancer* **10(1)**:4.

Vijaya , Sharma S, Batra N. 2019. Comparative study of single linkage, complete linkage, and ward method of agglomerative clustering. In: *2019 international conference on machine learning, big data, cloud and parallel computing (COMITCon)*. 568–573.

Voutsadakis IA. 2021. The landscape of chromosome instability in breast cancers and associations with the tumor mutation burden: an analysis of data from TCGA. *Cancer Investigation* **39(1)**:25–38 DOI 10.1080/07357907.2020.1863418.

Yurov YB, Vorsanova SG, Iourov IY. 2019. Chromosome instability in the neurodegenerating brain. *Frontiers in Genetics* **10**:892 DOI 10.3389/fgene.2019.00892.